Hypera Pharma Q2FY26 Results: Net profit rises 15% YoY, revenue up 8.5%
- Net revenue rose 8.5% YoY to R$2.34 billion, driven by 5% volume growth and price increases
- EBITDA reached R$755 million with a 32.3% margin; gross margin expanded to 61.8%
- Net income grew 15% YoY due to lower financial costs from prior quarter capital raise
- Net debt reduced to R$5.9 billion (2.1x EBITDA) supported by R$819 million operating cash flow
- Secured ANVISA approval for semaglutide and partnership for non-hormonal menopausal treatment
*this image is generated using AI for illustrative purposes only.
Hypera Pharma (OTC: HYPMY) reported an 8.5% year-on-year increase in net revenue to R$2.34 billion for the second quarter of FY26. The growth was driven by a nearly 5% rise in sales volume and price increases that outpaced input cost inflation.
The company achieved an EBITDA of R$755 million, representing a margin of 32.3%. Gross profit expanded by 11.5%, outpacing revenue growth by three percentage points due to improved pricing power and working capital efficiency.
Financial Performance
Hypera’s financial results for Q2FY26 reflect strong operational leverage and disciplined capital management. The company reduced its net debt to R$5.9 billion, equivalent to 2.1 times trailing twelve-month EBITDA.
| Metric | Q2FY26 Value | Change / Context |
|---|---|---|
| Net Revenue | R$2.34 billion | +8.5% YoY |
| Sell-out Growth | - | +7.6% YoY |
| Gross Margin | 61.8% | +1.7 pp vs Q2FY25 |
| EBITDA | R$755 million | 32.3% margin |
| Net Income | - | +15% YoY |
| Operating Cash Flow | R$819 million | 108.5% of EBITDA |
Net income grew by 15% primarily due to lower financial expenses following a R$1.5 billion capital raise in the previous quarter. Marketing expenses increased by 13.7% to R$411 million to support brand visibility and prescription product launches.
What the Numbers Show
Operating cash flow of R$819 million exceeded EBITDA for the period, indicating robust conversion of operating income into cash. This surplus was driven by structural improvements in working capital management, specifically the reduction of internal inventories of raw materials and finished goods. The efficiency gain allowed the company to reduce working capital investment to 28% of annualized net revenue, supporting the decline in net debt despite significant interest and amortization payments of approximately R$1.3 billion.
Strategic Developments
Hypera advanced its portfolio expansion with two key regulatory and partnership milestones:
- Secured ANVISA approval for semaglutide registration under the Mantecorp brand, entering the GLP-1 market which recorded R$15 billion in sales over the past 12 months.
- Announced a partnership to launch a non-hormonal menopausal treatment in Brazil, targeting a market estimated at over R$1 billion. The product is protected by a patent through 2034.
Management highlighted that new product launches contributed 2.2 percentage points to sell-out growth this quarter. The company plans to sustain marketing investments at current levels to support these launches, particularly in cardiology and endocrinology segments.
How might Hypera Pharma's entry into the competitive GLP-1 market with semaglutide impact its gross margins given the intense pricing pressure in this segment?
What is the projected timeline for the non-hormonal menopausal treatment to contribute significantly to revenue, and how will patent protection through 2034 influence long-term profitability?
Given the R$1.5 billion capital raise and reduced net debt, what is Hypera's strategy for allocating excess operating cash flow between further debt reduction, M&A, or share buybacks?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
